{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:47:23Z","timestamp":1791488843119,"version":"4.3.4"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Nirsevimab is highly effective in preventing respiratory syncytial virus (RSV) infection in healthy infants. Evidence among infants at higher risk of severe RSV disease, such as those born preterm or with congenital heart disease (CHD), remains limited to clinical settings.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association of nirsevimab with the prevention of RSV-related hospitalizations among at-risk infants after implementation of a universal immunization strategy in Chile.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This case-control study used nationwide health registries of all public and private hospitals in Chile during the 2024 RSV season following the launch of a universal RSV immunization program with nirsevimab. The case group included at-risk infants born preterm (gestational age &amp;lt;36 weeks) or with congenital heart disease (CHD) hospitalized for RSV-related lower respiratory tract infection (LRTI), while the control group included infants not hospitalized for RSV-related LRTI. Each case infant was matched to 4 control infants by age, prematurity or CHD status, and geographic region.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n A single intramuscular dose of nirsevimab administered to all infants born up to 6 months before April 1, 2024, and those born between April 1 and September 30, 2024.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n The main outcome was RSV-related LRTI hospitalization. Associations were assessed for at-risk infants and high-risk infants (born extremely preterm at gestational age &amp;lt;32 weeks or with CHD), with nirsevimab outcomes associated with RSV-related LRTI hospitalization estimated as (1 \u2212 adjusted odds ratio)\u2009\u00d7\u2009100, with 95% CIs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 179 RSV-related LRTI hospitalizations among at-risk infants (including 58 [32.4%] with extreme prematurity, 41 [22.9%] with CHD, and 87 [48.6%] without extreme prematurity and CHD [non\u2013high risk]; categories not mutually exclusive), 177 (median [IQR] age, 210.0 [148.0-266.0] days; 109 male [61.3%]) were successfully matched to 708 control infants (including 55 of 58 [94.8%] with extreme prematurity, 39 of 41 [95.1%] with CHD, and 87 [100%] non\u2013high risk; median [IQR] age, 210.5 [147.8-268.5] days; 393 male [55.5%]). A total of 156 case infants (88.1%) and 689 control infants (97.3%) received nirsevimab. In subgroup analyses, nirsevimab receipt in case vs control infants was 79 of 90 (87.8%) vs 351 of 360 (97.5%) among high-risk infants, 50 of 55 (90.9%) vs 213 of 220 (96.8%) among extremely preterm infants, 33 of 39 (84.6%) vs 153 of 156 (98.1%) among infants with CHD, and 77 of 87 (88.5%) vs 339 of 348 (97.4%) in non\u2013high-risk infants. Nirsevimab was associated with a reduced risk of RSV-related LRTI hospitalization of 84.3% (95% CI, 67.0%-92.5%) among all at-risk infants, 85.1% (95% CI, 60.2%-94.4%) among infants with extreme prematurity and CHD combined, and 96.3% (95% CI, 65.5%-99.6%) among infants with CHD but was not associated with a reduced risk for hospitalization among infants with extreme prematurity alone (65.9%; 95% CI, \u221210.8% to 89.5%).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This case-control study of Chile\u2019s nationwide nirsevimab immunization program found that RSV-related LRTI hospitalizations among infants at higher risk of severe disease were substantially reduced. These findings support replacing targeted palivizumab prophylaxis with a broader, universal nirsevimab strategy as part of RSV prevention policy.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.6042","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:30:59Z","timestamp":1775835059000},"page":"e266042","source":"Crossref","is-referenced-by-count":2,"title":["Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy"],"prefix":"10.1001","volume":"9","author":[{"given":"Denis","family":"Saur\u00e9","sequence":"first","affiliation":[{"name":"Industrial Engineering Department, Universidad de Chile, Santiago, Chile"},{"name":"Instituto Sistemas Complejos de Ingenier\u00eda, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Torres","sequence":"additional","affiliation":[{"name":"Instituto Sistemas Complejos de Ingenier\u00eda, Santiago, Chile"},{"name":"Department of Pediatrics and Pediatric Surgery, Facultad de Medicina, Universidad de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Goic","sequence":"additional","affiliation":[{"name":"Industrial Engineering Department, Universidad de Chile, Santiago, Chile"},{"name":"Instituto Sistemas Complejos de Ingenier\u00eda, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Thraves","sequence":"additional","affiliation":[{"name":"Industrial Engineering Department, Universidad de Chile, Santiago, Chile"},{"name":"Instituto Sistemas Complejos de Ingenier\u00eda, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Pacheco","sequence":"additional","affiliation":[{"name":"Departamento de Estad\u00edsticas e Informaci\u00f3n de Salud, Ministerio de Salud de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javiera","family":"Burgos","sequence":"additional","affiliation":[{"name":"Departamento de Estad\u00edsticas e Informaci\u00f3n de Salud, Ministerio de Salud de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Zgheib","sequence":"additional","affiliation":[{"name":"Instituto Sistemas Complejos de Ingenier\u00eda, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"del Solar","sequence":"additional","affiliation":[{"name":"Instituto Sistemas Complejos de Ingenier\u00eda, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi","family":"Neira","sequence":"additional","affiliation":[{"name":"Instituto Sistemas Complejos de Ingenier\u00eda, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"O\u2019Ryan","sequence":"additional","affiliation":[{"name":"Instituto Sistemas Complejos de Ingenier\u00eda, Santiago, Chile"},{"name":"N\u00facleo de Microbiolog\u00eda y Virolog\u00eda, Instituto de Ciencias Biom\u00e9dicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo J.","family":"Basso","sequence":"additional","affiliation":[{"name":"Industrial Engineering Department, Universidad de Chile, Santiago, Chile"},{"name":"Instituto Sistemas Complejos de Ingenier\u00eda, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"10098","key":"zoi260212r1","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study.","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"issue":"10340","key":"zoi260212r2","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"zoi260212r3","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/S1473-3099(25)00233-6","article-title":"Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy (NIRSE-CL): a retrospective observational study.","volume":"25","author":"Torres","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"zoi260212r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2025.102680","article-title":"Cost-savings and health impact of strategies for prevention of respiratory syncytial virus with nirsevimab in Chile based on the integrated analysis of 2019-2023 national databases: a retrospective study.","volume":"18","author":"Saur\u00e9","year":"2025","journal-title":"J Infect Public Health"},{"issue":"8","key":"zoi260212r5","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.","volume":"24","author":"Ares-G\u00f3mez","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"zoi260212r6","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/archdischild-2024-327153","article-title":"Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain).","volume":"109","author":"Coma","year":"2024","journal-title":"Arch Dis Child"},{"issue":"5","key":"zoi260212r7","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2025.30.5.2400596","article-title":"Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023\/24 season.","volume":"30","author":"N\u00fa\u00f1ez","year":"2025","journal-title":"Euro Surveill"},{"issue":"5","key":"zoi260212r8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/INF.0000000000004672","article-title":"Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital care settings: a seasonal cohort study of infants in Catalonia, Spain.","volume":"44","author":"Perramon-Malavez","year":"2025","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"zoi260212r9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S2352-4642(24)00171-8","article-title":"Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case-control study in Paris, France.","volume":"8","author":"Carbajal","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"issue":"6","key":"zoi260212r10","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13311","article-title":"Nirsevimab effectiveness against cases of respiratory syncytial virus bronchiolitis hospitalised in paediatric intensive care units in France, September 2023-January 2024.","volume":"18","author":"Paireau","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"issue":"3","key":"zoi260212r11","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400275","article-title":"Nirsevimab effectiveness at preventing RSV-related hospitalization in infants.","volume":"4","author":"Jabagi","year":"2025","journal-title":"NEJM Evid"},{"issue":"9","key":"zoi260212r12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalization among infants entering their first respiratory syncytial virus season - New Vaccine Surveillance Network, October 2023-February 2024.","volume":"73","author":"Moline","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"zoi260212r13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jamapediatrics.2024.5572","article-title":"Respiratory syncytial virus disease burden and nirsevimab effectiveness in young children from 2023-2024.","volume":"179","author":"Moline","year":"2024","journal-title":"JAMA Pediatr"},{"issue":"45","key":"zoi260212r14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.15585\/mmwr.mm7345a1","article-title":"Nirsevimab effectiveness against medically attended respiratory syncytial virus illness and hospitalization among Alaska Native children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024.","volume":"73","author":"Lefferts","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi260212r15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00431-025-06050-7","article-title":"Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3 months: a retrospective study.","volume":"184","author":"Marouk","year":"2025","journal-title":"Eur J Pediatr"},{"issue":"3","key":"zoi260212r16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.","volume":"7","author":"Sim\u00f5es","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"16","key":"zoi260212r17","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1056\/NEJMc2214773","article-title":"Nirsevimab for prevention of RSV in term and late-preterm infants.","volume":"388","author":"Muller","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi260212r18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirservimab for prevention of RSV in healthy late-preterm and term infants.","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi260212r19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants.","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"zoi260212r20","unstructured":"Ministerio de Salud. Crea un sistema de protecci\u00f3n financiera para diagn\u00f3sticos y tratamientos de alto costo y rinde homenaje p\u00f3stumo a Don Luis Ricarte Soto Gallegos. Biblioteca del Congreso Nacional de Chile. June 6, 2015. Accessed March 6, 2026. https:\/\/www.bcn.cl\/leychile\/navegar?idNorma=1078148"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847637\/saur_2026_oi_260212_1775233644.24353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:31:03Z","timestamp":1775835063000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.6042","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]}}}